20 Participants Needed

Exercise for Cancer Immunotherapy Response

(EX-BOOST Trial)

RD
Overseen ByRecruitment Department
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: AdventHealth Translational Research Institute
Must be taking: Checkpoint immunotherapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, and ii) preliminary data on the impact of a day-of-therapy exercise intervention.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Exercise, Physical Activity, Workout, Fitness Training for improving cancer immunotherapy response?

Research shows that exercise can enhance the immune system's response to cancer treatments by improving blood flow to tumors and increasing the activity of immune cells. This suggests that exercise may help make cancer immunotherapy more effective.12345

Is exercise safe for humans in the context of cancer immunotherapy?

Exercise is generally considered safe for humans and has been shown to improve outcomes in cancer patients by enhancing the immune system. While specific safety data for exercise combined with cancer immunotherapy is limited, exercise is widely recognized for its health benefits and is associated with reduced cancer recurrence and mortality.12367

How does exercise as a treatment differ from other cancer treatments?

Exercise is unique as a cancer treatment because it enhances the body's immune response and improves blood flow to tumors, potentially boosting the effectiveness of immunotherapy. Unlike traditional treatments like chemotherapy or radiation, exercise is a non-invasive approach that can be used alongside other therapies to improve outcomes.12389

Research Team

BG

Bret Goodpaster, PhD

Principal Investigator

Study Principal Investigator

Eligibility Criteria

This trial is for adults over 18 who speak English and are about to start checkpoint blockade immunotherapy for the first time, targeting skin cancers like melanoma. They must be able to do moderate exercise, follow the study protocol, and not have severe health issues that make exercise unsafe.

Inclusion Criteria

I have signed the consent form and agreed to share my health information for this study.
States willingness to follow protocol as described, including the prescribed exercise level and completing any forms needed throughout the study
I can walk unaided for six minutes or more.
See 1 more

Exclusion Criteria

I have major complications after surgery that may prevent me from exercising.
Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study
Currently pregnant, lactating or planning to become pregnant (positive result on urine pregnancy testing)
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive checkpoint blockade immunotherapy with or without a same-day exercise intervention

Up to 12 months
Visits coincide with each immunotherapy cycle

Follow-up

Participants are monitored for relapse-free and recurrence-free survival

Up to 12 months

Treatment Details

Interventions

  • Exercise
Trial Overview The study tests if exercising on the day you get immunotherapy (with drugs like avelumab or pembrolizumab) is feasible and affects treatment outcomes in patients with certain skin cancers.
Participant Groups
4Treatment groups
Active Control
Group I: Intervention Group- Moderate Exercise (adjuvant)Active Control1 Intervention
Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
Group II: Intervention Group- Moderate Exercise (Neoadjuvant)Active Control1 Intervention
Patients randomized to the exercise arm will complete up to 30 minutes of same-day exercise prior to each administration of checkpoint blockade immunotherapy across all cycles. The preferred exercise is 30 minutes of moderate exertion on a cycle ergometer.
Group III: Standard Group- No Exercise (Neoadjuvant)Active Control1 Intervention
Patients randomized to the standard arm will receive clinical care following AH (AdventHealth) standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.
Group IV: Standard Group- No Exercise (Adjuvant)Active Control1 Intervention
Patients randomized to the standard arm will receive clinical care following AH standards for the patient's disease type and therapeutic setting. This includes history and physical and laboratory studies to be conducted on each infusion day before clearing the patient for infusion.

Find a Clinic Near You

Who Is Running the Clinical Trial?

AdventHealth Translational Research Institute

Lead Sponsor

Trials
51
Recruited
5,900+

Findings from Research

Observational studies suggest that both physical activity and structured exercise can significantly reduce the risk of cancer recurrence and mortality, highlighting their potential role in cancer recovery.
Emerging preclinical evidence indicates that exercise may enhance the effectiveness of standard cancer treatments like chemotherapy and radiotherapy by improving tumor blood flow, oxygen levels, and immune responses.
Exercise as Adjunct Therapy in Cancer.Ashcraft, KA., Warner, AB., Jones, LW., et al.[2020]
Exercise and physical activity can enhance immune function in cancer patients, potentially improving their responses to immunotherapies like immune checkpoint inhibitors and CAR T cell therapies.
Chronic exercise is linked to better physical fitness and a healthier immune profile, including reduced dysfunctional T cells, suggesting that incorporating exercise into cancer treatment plans could lead to better outcomes.
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy.Gustafson, MP., Wheatley-Guy, CM., Rosenthal, AC., et al.[2023]
In a study involving mice with breast and melanoma tumors, exercise combined with anti-PD-1 immunotherapy increased the percentage of CD8+ T cells in breast tumors, suggesting a potential enhancement of anti-tumor immune responses.
The effects of exercise on the immune environment varied by tumor type, indicating that while exercise may improve the efficacy of immunotherapy in some cancers, its impact is not uniform across different tumor types.
Effects of exercise and anti-PD-1 on the tumour microenvironment.Buss, LA., Williams, T., Hock, B., et al.[2022]

References

Exercise as Adjunct Therapy in Cancer. [2020]
Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. [2023]
Effects of exercise and anti-PD-1 on the tumour microenvironment. [2022]
Can Exercise Enhance the Efficacy of Checkpoint Inhibition by Modulating Anti-Tumor Immunity? [2023]
Exercise reduces immune suppression and breast cancer progression in a preclinical model. [2020]
Physical activity and checkpoint inhibition: association with toxicity and survival. [2023]
Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. [2022]
Exercise Benefits Meet Cancer Immunosurveillance: Implications for Immunotherapy. [2021]
Exercise-Induced Changes in Tumor Growth via Tumor Immunity. [2021]